Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
THF dehydrogenase inhibitor
DRUG CLASS:
THF dehydrogenase inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
pemetrexed (58)
methotrexate (37)
pralatrexate (2)
LX-101 (0)
pemetrexed (0)
methotrexate oral solution (0)
ADX-2191 (0)
methotrexate IV (0)
pemetrexed (58)
methotrexate (37)
pralatrexate (2)
LX-101 (0)
pemetrexed (0)
methotrexate oral solution (0)
ADX-2191 (0)
methotrexate IV (0)
›
Associations
(97)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
cisplatin + pemetrexed
Sensitive: A1 - Approval
cisplatin + pemetrexed
Sensitive
:
A1
cisplatin + pemetrexed
Sensitive: A1 - Approval
cisplatin + pemetrexed
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
pemetrexed
Sensitive: A1 - Approval
pemetrexed
Sensitive
:
A1
pemetrexed
Sensitive: A1 - Approval
pemetrexed
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin + pemetrexed RTD
Sensitive: A1 - Approval
cisplatin + pemetrexed RTD
Sensitive
:
A1
cisplatin + pemetrexed RTD
Sensitive: A1 - Approval
cisplatin + pemetrexed RTD
Sensitive
:
A1
No biomarker
Malignant Pleural Mesothelioma
No biomarker
Malignant Pleural Mesothelioma
cisplatin + pemetrexed
Sensitive: A1 - Approval
cisplatin + pemetrexed
Sensitive
:
A1
cisplatin + pemetrexed
Sensitive: A1 - Approval
cisplatin + pemetrexed
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
pemetrexed
Sensitive: A1 - Approval
pemetrexed
Sensitive
:
A1
pemetrexed
Sensitive: A1 - Approval
pemetrexed
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin + pemetrexed
Sensitive: A1 - Approval
cisplatin + pemetrexed
Sensitive
:
A1
cisplatin + pemetrexed
Sensitive: A1 - Approval
cisplatin + pemetrexed
Sensitive
:
A1
No biomarker
Malignant Pleural Mesothelioma
No biomarker
Malignant Pleural Mesothelioma
pemetrexed
Sensitive: A1 - Approval
pemetrexed
Sensitive
:
A1
pemetrexed
Sensitive: A1 - Approval
pemetrexed
Sensitive
:
A1
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
pralatrexate
Sensitive: A1 - Approval
pralatrexate
Sensitive
:
A1
pralatrexate
Sensitive: A1 - Approval
pralatrexate
Sensitive
:
A1
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
methotrexate
Sensitive: A1 - Approval
methotrexate
Sensitive
:
A1
methotrexate
Sensitive: A1 - Approval
methotrexate
Sensitive
:
A1
No biomarker
Oral Cancer
No biomarker
Oral Cancer
methotrexate
Sensitive: A2 - Guideline
methotrexate
Sensitive
:
A2
methotrexate
Sensitive: A2 - Guideline
methotrexate
Sensitive
:
A2
No biomarker
Oropharyngeal Cancer
No biomarker
Oropharyngeal Cancer
methotrexate
Sensitive: A2 - Guideline
methotrexate
Sensitive
:
A2
methotrexate
Sensitive: A2 - Guideline
methotrexate
Sensitive
:
A2
No biomarker
Malignant Pleural Mesothelioma
No biomarker
Malignant Pleural Mesothelioma
carboplatin + pemetrexed
Sensitive: A2 - Guideline
carboplatin + pemetrexed
Sensitive
:
A2
carboplatin + pemetrexed
Sensitive: A2 - Guideline
carboplatin + pemetrexed
Sensitive
:
A2
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.